Remedium Capital Partners, LLC
•CIK: 2104501•Filing: Q4 2025
**Remedium Capital Partners, LLC** manages $170M across a concentrated portfolio of six positions. The fund exhibits significant conviction in its top holdings, with SYRE, ORKA, and APGE comprising the majority of capital at $47.7M, $47.1M, and $44.0M, respectively. This allocation structure suggests a focused, high-conviction approach within its investment mandate. The remaining capital is deployed across smaller, targeted positions in JBIO, CBIO, and GLTO.
Total AUM
$170.2M
QoQ Performance
N/A
Positions
6
Top 10 Concentration
100.0%
Latest Filing
Q4 2025
Top Holdings Allocation
SYRE
ORKA
APGE
JBIO
SYRE28.0%
ORKA27.6%
APGE25.9%
JBIO14.3%
Crescent2.5%
DMRA1.6%
📈 Biggest Buys
📉 Biggest Sells
No reductions this quarter
Sector Breakdown
Other100.0%